AlphaLiquid®100 genetic tumour test
An innovative liquid biopsy test that analyses tumour DNA circulating in the blood and detects clinically relevant alterations across 118 genes, supporting treatment selection and monitoring of treatment response. The test enables personalised care for patients with solid tumours.
More precise treatment starts with tumour DNA
Successful cancer treatment depends on accurately understanding how an individual patient’s tumour will respond to different therapies. Traditional biopsies are not always feasible or sufficient, and a tumour’s genetic profile can change during treatment. AlphaLiquid®100 analyses circulating tumour DNA in blood, enabling clinicians to make data-driven decisions – both when selecting therapy and when evaluating effectiveness or relapse risk.
What exactly does AlphaLiquid®100 analyse?
AlphaLiquid®100 is a highly sensitive genetic test that analyses circulating tumour DNA (ctDNA) to identify genetic changes that influence treatment decisions and disease course. The test is performed using next-generation sequencing (NGS) and UniqSeq® technology.
ctDNA (tumour genetic material) is identified from a 20 ml blood sample
Analyses alterations in 118 cancer-relevant genes
Detects treatment-relevant mutations (e.g., target sensitivity, resistance mechanisms)
Enables monitoring of how the tumour genetic profile changes during treatment
Assesses relapse risk by detecting emerging mutation markers
Personalised oncology care: when decisions are guided by your tumour genetics
AlphaLiquid®100 supports selection of the most effective treatment based on the patient’s tumour-specific genetic alterations. This is especially valuable when tissue biopsy is not possible or when existing biopsy data are outdated. The test also enables monitoring tumour dynamics during treatment and responding to genetic changes in time.
Targeted treatment based on 118-gene analysis
The report provides detailed information on genetic alterations that may affect response to targeted therapy, chemotherapy, or immunotherapy.
Non-invasive and safe
Only a blood sample is required — no invasive procedures — making the test suitable even for patients in complex clinical condition.
Real-time monitoring of treatment course
By repeating the test, clinicians can track whether new mutations emerge that may indicate treatment failure or relapse.
Decision support when biopsies aren’t possible
Provides essential genetic information even when tumour tissue cannot be obtained or is insufficient for analysis.
When and for whom is the test recommended?
For patients who cannot undergo a standard tumour biopsy
When the tumour is not accessible for invasive sampling or the patient’s condition does not allow a surgical procedure.
When biopsy material is insufficient for genetic testing
Especially useful when too little tissue is obtained to perform comprehensive genetic analysis.
For patients with outdated genetic profiling
If significant time has passed since the last tumour genetic test and the disease course has changed, AlphaLiquid®100 helps update the information.
When more than one mutation has been identified
Helps clarify which mutations are active and how they may affect treatment effectiveness.
AlphaLiquid®100 reliability: accuracy and quality metrics
The test uses advanced UniqSeq® technology and next-generation sequencing (NGS), enabling detection of very low concentrations of ctDNA in blood. This delivers very high sensitivity and accuracy.
Analysis of 118 cancer-relevant genes from a single blood sample
UniqSeq® – patented technology optimised for ctDNA sequencing
Personalised oncology treatment
Take the AlphaLiquid®100 test and find out which treatment is most effective in your case.
For Specialists
All key information in one place – from the genes analysed to test accuracy and clinical value. This section is intended for specialists who want a detailed understanding of the test rationale, structure, and practical applications.
AlphaLiquid®100 is a minimally invasive liquid biopsy test designed for genomic profiling of advanced solid tumours. It enables tumour genotyping, supports selection of a personalised treatment strategy, and allows real-time monitoring of treatment response. Because it analyses ctDNA circulating in blood, it is particularly useful when tissue biopsy is not possible or provides limited information.
The test covers 118 clinically relevant genes, including 38 drug targets, 15 homologous recombination repair (HRR) genes, and 10 gene fusions. This enables comprehensive evaluation of tumour genetics and selection of targeted treatment based on an individual tumour profile.
Sensitivity and accuracy are supported by 50,000× sequencing depth and 8,000×+ unique molecule coverage. Results show 90–95% concordance with tumour tissue genetic findings. Performance is supported by analysis of 10,000+ clinical samples.
AlphaLiquid®100 identifies:
- Single-nucleotide variants (SNVs)
- Insertions and deletions (InDels)
- Copy number alterations (CNAs)
- Gene fusions
- HRR gene alterations
It also reports tumour biomarkers such as microsatellite instability (MSI) and tumour mutational burden (TMB).
Longitudinal ctDNA profiling with AlphaLiquid®100 helps assess tumour spatial heterogeneity and track the systemic genomic landscape. With repeat testing, resistance mutations can be detected, treatment effectiveness monitored, and relapse predicted before clinical signs appear.
